TheStreet.com  Apr 3  Comment 
NEW YORK (TheStreet) -- Amyris was jumping 17.4% to $4.73 Thursday following the announcement of a new strain engineering research and development agreement with BASF SE . As part of the agreement Amyris will use its strain engineering...
StreetInsider.com  Apr 3  Comment 
SGOCO Group, Ltd (Nasdaq:  SGOC ) 31.4 % LOWER;   reported Q4 EPS of $0.07, versus $0.19 reported last year. Revenue for the quarter came in at $44.2 million, versus $63.4 million reported last year. BG Medicine, Inc....
Benzinga  Apr 3  Comment 
Amyris (NASDAQ: AMRS) shares jumped 16.13% to $4.68 in pre-market trading after the company and BASF reached an agreement for strain engineering collaboration. Plug Power (NASDAQ: PLUG) shares gained 4.95% to $7.85 in the pre-market after the...
StreetInsider.com  Apr 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AMYRIS+%28AMRS%29%2C+BASF+SE+Enter+%27Collaborative+Research+and+Development+Agreement%27/9348160.html for the full story.
TheStreet.com  Apr 1  Comment 
NEW YORK (TheStreet) -- Amyris was gaining 19.3% to $4.45 Tuesday following the release of a renewable fuel study from the United States Maritime Administration. In the report MARAD said is finished tests of renewable biofuel technology on the...
Biomass Magazine  Mar 31  Comment 
Amyris Inc. and Kuraray Co. Ltd. have announced a two year expansion and extension of the research and development portion of their ongoing collaboration in high performance polymers using Biofene, Amyris's brand of renewable farnesene.
SeekingAlpha  Mar 7  Comment 
By The Street Sweeper: The plan by Amyris (AMRS) to provide "clean" bio-engineered jet fuel, facial cream and perfume looks as buggy as the jiggered microbes that actually create the products. TheStreetSweeper has uncovered the dirty little...
Biomass Magazine  Feb 27  Comment 
Amyris Inc. has released its fourth quarter and full year 2013 financial results. The company reported total revenues of $41.12 million for the year, down from $73.69 million in 2012.
SeekingAlpha  Feb 26  Comment 
By Kevin Quon: On Tuesday, leading renewable chemicals and fuel company, Amyris (AMRS) saw its share price jump more than 20% intraday, as the company reported its 2013 year-end results. While missing on both the revenue and the earnings, the...


Amyris Biotechnologies (NASDAQ:AMRS) creates, sells, and distributes renewable products that replace chemicals and fuels made from petroleum. Amyris genetically modifies yeast cells to ferment feedstocks into a series of different target molecules. The company then sells these target molecules to replace additives or fuels which are made from petroleum. The company originally focused on using sugar cane stalks and turned them into farnesene which is key additive in detergents, cosmetics, and transportable fuels among other things. Amyris has continued to diversify both the inputs it can take and the output molecules it can produce. Amyris has pushed to make its products competitive, both in price and effectiveness of replacement, even if they are renewable.[1]

Amyris currently does not have any commercial level efforts in place. It has only established a test facility next to its laboratories in California. The company hopes to expand to commercial distribution levels during 2011 by establishing contracts with sugar cane mills in Brazil. The company has agreed through a letter of intent with a large Brazilian manufacturer to establish a joint venture facility which would turn 10% of their sugar cane into farnesene.[2] The company has also entered into commercialization agreements with large chemical and cosmetic companies such as Procter & Gamble Company (PG).[3]

The company's initial public offering of stock filed on the NASDAQ and went public on the 27 of September 2010. It priced at $16, which was well below the initial price range of $18-$20. The company raised $85M by offering 5.3M shares. The lead underwriter of the deal were J P Morgan Chase (JPM), Morgan Stanley (MS), and Goldman Sachs Group (GS).[4]

Despite not producing at commercial levels, the company has achieved a net revenue for 2009 of $65M. However, due to the high Research & Development costs associated to its developmental stage, it incurred a net loss of $64M.[5]


  1. AMRS S-1/A 2010 "Our Company" pg 1
  2. AMRS S-1/A 2010 "Commercial Production" pg 2
  3. AMRS S-1/A 2010 "Commercialization and Distribution" pg 2
  4. Renaissance Capital - IPO "Amyris Biotechnologies prices IPO at $16, below the proposed range" 28 Sept 2010
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki